In breast cancer, biomaterials targeting transferrin receptor were tested in primary orthotopic tumors [5, 8, 9, 25–28, 86, 87], where a 70% average prevalence of TfR expression is well established [20, 21, 63]. This evidence concerns the gene TFRC and breast carcinoma.